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Abstract (85 words): Streptococcus pyogenes (group A streptococcus) causes human skin and 
throat infections as well as highly invasive diseases including necrotising fasciitis. Group A 
streptococcal infections and invasive disease have made a resurgence in developed countries 
over the last two decades. S. pyogenes utilise multiple pathways for the acquisition and 
activation of human plasminogen, securing potent proteolytic activity on the bacterial cell 
surface. Recent experimental evidence using a humanised transgenic mouse model suggests a 
critical role for human plasminogen in the dissemination of S. pyogenes in vivo.  
 
Invasive diseases caused by S. pyogenes: Group A streptococcus (Streptococcus pyogenes) 
causes a variety of illnesses with diverse clinical manifestations (see text box) [1]. Since the mid-
1980’s, there has been a global resurgence of severe invasive group A streptococcal infections 
[2-4]. These diseases progress rapidly and are associated with high rates of morbidity and 
mortality despite the prompt use of antibiotics. Infection rates have persisted over the last 20 
years which has spurred new research into identifying host susceptibility factors and bacterial 
determinants that may explain these epidemiological changes. 
 
Although no single group A streptococcal virulence determinant has been exclusively associated 
with a specific disease type, early research identified an association between certain M protein 
serotypes (i.e. M1 and M3) and invasive infections [5]. Numerous other studies from the 1990’s 
suggested that the resurgence of invasive group A streptococcal infections was due to the 
emergence of “highly virulent” strains that were clonal in origin [6-11]. Nonetheless, more 
recent studies examining larger strain sets and using more powerful methodologies to 
characterise the subtle genetic diversity among isolates have failed to demonstrate a significant 
association between any particular group A streptococcal clone and invasive infections [12].  
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S. pyogenes strains of M1T1 and M3 serotypes can be isolated from both uncomplicated 
infections such as pharyngitis and severe invasive infections such as necrotising fasciitis [5,13]. 
These group A streptococcal strains can also vary greatly in disease frequency and exhibit 
epidemic behaviour suggesting these strains are capable of rapid genetic change. Beres et al. [14] 
found that the major generator of distinct genotypes within 255 group A streptococcal strains 
(serotype M3) was the acquisition and loss of prophages encoding known and putative virulence 
factors. This molecular process combined with altered immune recognition due to a four amino 
acid change in the N-terminal region of the M protein is believed to have significantly 
contributed to an epidemic wave of M3 invasive infections [14]. Phage sequences present in the 
two sequenced M3 genomes have also been detected in the genome of S. pyogenes M1T1, a 
strain that is often isolated from invasive diseases [15]. The genetic mosaicism and unique gene 
sequences present in these phage cassettes act as additional sources of genetic variability and 
suggest phages can be shared between different M serotypes and even different bacterial species 
[15]. Host genetic factors have also been shown to play an important role in determining the 
severity of invasive group A streptococcal infections by altering the magnitude of the cytokine 
and inflammatory responses against secreted streptococcal pyrogenic exotoxins [16,17].  
 
Common to all invasive group A streptococcal diseases is the requirement of the bacteria to gain 
entry into areas of the body that are normally sterile sites. Plasminogen binding and its activation 
to the broad-spectrum serine protease plasmin has been implicated as a contributing mechanism 
of invasion for S. pyogenes and a variety of other bacterial species [18,19].  
 
Binding of plasminogen to the group A streptococcal cell surface: Plasminogen is the 
multidomain, 791 amino acid circulating zymogen form of plasmin.  Plasminogen contains five 
kringle domains with lysine-binding sites identified in kringles 1, 2, 4 and 5 which are 
responsible for binding to fibrinogen and plasminogen receptors [20]. Two pathways have been 
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described in the literature for the binding of plasminogen to the group A streptococcal cell 
surface. Direct plasminogen binding is meditated by the three known surface plasminogen 
receptors: plasminogen-binding group A streptococcal M-like protein (PAM or M53; [21]), α-
enolase (surface enolase or SEN; [22]) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), alternatively known either as plasminogen receptor (Plr) or streptococcal surface 
dehydrogenase (SDH) [22,23]. Additionally, indirect binding of plasminogen is mediated by the 
formation of a trimolecular complex consisting of plasminogen, streptokinase and fibrinogen. 
This complex is then bound to the group A streptococcal cell surface via either plasminogen or 
fibrinogen receptors [24-26]. 
 
Of the three known plasminogen receptors, published evidence suggests that PAM makes the 
largest contribution to direct plasminogen binding by group A streptococci. In two independent 
studies, PAM-positive S. pyogenes isolates have been found to bind significantly higher levels of 
plasminogen than PAM-negative isolates [26,27] (Figure 1A). Svensson et al. [27] found an 
association between PAM-positive isolates and impetigo. Nonetheless, in a study of group A 
streptococcal isolates from the Northern Territory of Australia where skin infections are 
endemic, PAM-positive isolates were found to cause bacteremia, throat and skin infections [26]. 
Binding of PAM to plasminogen is mediated by amino-terminal plasminogen-binding tandem 
repeat motifs containing lysine residues (designated a1 and a2) in the PAM molecule, which 
interact with the lysine binding kringle 2 domain of plasminogen [21,28,29].  
 
Plasminogen has been reported to bind to cell-surface located glycolytic enzymes α-enolase and 
GAPDH [22,23]. Both GAPDH and α-enolase interact with lysine binding kringles domain of 
plasminogen via carboxy-terminal lysine residues [22,30]. Such carboxy-terminal lysine residues 
usually bind to kringle 1, 4 and 5 of plasminogen [20]. Whilst α-enolase has been described as a 
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high affinity plasminogen receptor [22], the failure of PAM-negative isolates to bind significant 
levels of plasminogen by the direct binding pathway [26,27] suggests that α-enolase may play a 
more prominent role in the indirect binding pathway by interacting with a trimolecular complex 
consisting of plasminogen, streptokinase and fibrinogen (Figure 1A). GAPDH has been reported 
to bind plasminogen with low affinity [22]. Neither GAPDH nor α-enolase contain known 
secretion signals or membrane anchor motifs and the mechanism by which these glycolytic 
enzymes become surface exposed is unknown. Both enzymes have also been detected in S. 
pyogenes culture supernatants [31,32]. Other researchers have suggested hypotheses to account 
for cell-surface GAPDH and α-enolase including the release of such proteins from group A 
streptococcal cells by autolysis with the released protein potentially binding back to the surface 
of neighbouring cells or the existence of a hitherto uncharacterised transport mechanism [22,33]. 
Recently, asymmetric protein secretion of streptococcal pyrogenic exotoxin B (SpeB) was shown 
to occur at distinct cytoplasmic membrane microdomains termed ExPortals [34]. The role that 
this structure plays in the secretion of other S. pyogenes proteins is currently unknown. However, 
GAPDH and α-enolase are also asymmetrically distributed on the GAS cell surface [22,33,35], 
reminiscent of the distribution of SpeB at the GAS ExPortal (Figure 2). We therefore 
hypothesise that both GAPDH and α-enolase are secreted from the group A streptococcal cell 
via the ExPortal then subsequently bind to the cell surface. 
 
As mentioned above, the indirect plasminogen-binding pathway in S. pyogenes requires 
streptokinase and fibrinogen [24,25,36] (Figure 1A). Takada and Takada [36] first reported the 
capacity of plasminogen, fibrinogen and streptokinase to form a trimolecular complex. This 
complex, which forms extracellularly then binds to the surface of group A streptococci, 
possesses both plasmin [25] and plasminogen-activator [37] activities. This pathway may 
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represent the primary plasminogen surface-acquisition mechanism in PAM-negative S. pyogenes 
isolates. 
 
Acquisition of surface plasmin: The conversion of plasminogen to plasmin can be achieved by 
either the mammalian plasminogen activators urokinase (uPA) and tissue plasminogen activator 
(tPA), or by secreted microbial activators such as streptokinase [19,20]. As distinct from tPA or 
uPA, which directly cleave the plasminogen activation bond (i.e. Arg561-Val562) to generate 
plasmin, streptokinase has no protease activity and cannot directly cleave this bond. Instead, 
streptokinase forms a 1:1 complex with plasminogen. The preferred catalytic substrate of this 
complex is the activation loop of other plasminogen molecules [38]. Plasminogen bound to the 
group A streptococcal surface can also interact with streptokinase leading to bacterium bound 
plasmin activity [25,37,39]. Additionally, tPA and uPA have been shown to activate 
plasminogen bound to the group A streptococcal surface [21,40] (Figure 3A). The streptokinase-
plasminogen activator complex and surface-bound plasmin cannot be inhibited by host plasmin 
inhibitors (i.e. α2-antiplasmin and α2-macroglobulin) [19,41]. This suggests a propensity of S. 
pyogenes for unregulated plasminogen activation capacity and plasmin activity regardless of host 
inhibitors. 
 
However, Tewodros et al. [42] found no correlation between secreted streptokinase activity in 
vitro and disease manifestation. Furthermore, high plasminogen binding strains were found to 
secrete low levels of streptokinase activity [42] (Figure 1B). Phylogenetic analysis of the β-
domain region of the gene encoding streptokinase (ska) revealed 2 major sequence clusters 
(clusters 1 and 2) [43]. Most PAM-positive strains possess the subcluster 2b ska allele. PAM-
negative strains fall into either cluster 1 or subcluster 2a ska alleles [43]. Interestingly, PAM-
positive strains are high plasminogen binders and acquire streptokinase-dependent and/or tPA-
dependent surface plasmin activity (Figure 1C) yet secrete low levels of active streptokinase [39] 
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(Figure 1B). The lack of streptokinase activity is possibly attributable to the expression of the 
cysteine protease SpeB in stationary phase cultures which degrades streptokinase [39]. On the 
other hand, relatively high levels of active streptokinase are secreted by low plasminogen 
binding strains [42] (Figure 1B). An alternative explanation for these observations may be 
related to the various ska alleles. Kalia and Bessen [43] proposed that subcluster 2b forms of 
streptokinase have adapted for interaction with plasminogen in the open conformation induced 
by binding to PAM rather than the closed circulating form of plasminogen (i.e. in solution phase) 
preferred by the other subcluster forms of streptokinase (Figure 3B and 3C, respectively). Thus, 
if subcluster 2b forms of streptokinase can only form streptokinase-plasminogen activator 
complexes when surface bound to PAM, this may account for the apparent lack of streptokinase 
activity in the supernatants of PAM-positive strains (Figure 1B). Non-cluster 2b forms of 
streptokinase may interact with both free and surface-bound forms of plasminogen (Figure 3C). 
 
Contribution of plasmin to the dissemination of S. pyogenes:  The importance of plasminogen 
in streptococcal pathogenicity is defined by the biochemical and molecular evolution of 
streptococcal plasminogen activation. The interaction of streptokinase with plasminogen reflects 
the mammalian host range of various streptococcal species [44] [45]. The species specificity of 
plasminogen activation and its importance in virulence are exemplified in murine models of 
group A streptococcal infection, where murine plasminogen is resistant to activation by S. 
pyogenes streptokinase [46] and mice are generally resistant to skin infection with S. pyogenes 
[47]. Accordingly, a high streptokinase-producing S. pyogenes strain and its streptokinase-
deletion mutant show no difference in virulence in a mouse skin infection model [48]. In 
contrast, when a source of human plasminogen is present at the infection site, the presence of the 
streptokinase gene markedly enhances group A streptococcal virulence [39,48]. Likewise, 
virulence of streptokinase-producing S. pyogenes is enhanced in the mouse by preincubation in 
human plasma, but not plasminogen-depleted plasma [49]. 
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The recently developed humanised plasminogen transgenic mouse model of infection 
definitively demonstrated the critical role of human plasminogen in group A streptococcal 
pathogenicity in vivo. The presence of a human plasminogen transgene markedly increased 
mortality following skin infection with S. pyogenes, but not intravenous infection. The 
susceptibility conferred by the human plasminogen transgene is dependent on streptokinase 
secretion by S. pyogenes, and is characterized by enhanced bacterial dissemination. Fibrinogen 
may be essential to host defense against group A streptococcal skin infection, possibly due to 
encapsulation of the bacteria within fibrin networks and prevention of systemic access by 
occlusion of the local vasculature. Acquisition of fibrinolytic activity by S. pyogenes 
circumvents fibrin-dependent mechanisms, even if only transiently, thereby enhancing virulence 
[47].  
 
Even in the absence of streptokinase, the ability to focus plasminogen at the group A 
streptococcal surface via cell-surface receptors enhances virulence in vivo. A streptokinase-
deficient S. pyogenes strain with plasminogen-binding capacity showed enhanced virulence 
when a human plasminogen source was provided, probably due to plasmin formation by host 
activators, tPA or uPA [48]. Human plasminogen is more readily activated by murine tPA than is 
murine plasminogen [46]. The binding of plasminogen to S. pyogenes is known to markedly 
increase the rate of plasminogen activation by tPA [40] supporting the hypothesis that cell-
surface binding of plasminogen is an important component of group A streptococcal 
pathogenesis.  
 
Conclusion: Current knowledge of the mechanisms of plasmin(ogen) binding to the S. pyogenes 
cell surface, the activation of surface acquired plasminogen and the contribution of this protease 
to the dissemination of group A streptococci in vivo suggests plasmin(ogen) plays an important 
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role in invasive disease progression. Elucidation of the mechanism(s) by which human 
plasminogen is bound to the group A streptococcal surface and activated may reveal new targets 
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Figures and Text Box 
 
Figure 1. Plasminogen binding and activation by PAM-positive and PAM-negative S. pyogenes 
isolates. (A) Group A streptococcal binding of 125I-plasminogen alone (hatched bars) or in the 
presence of excess streptokinase and fibrinogen (filled bars; data from [26]). (B) Streptokinase 
activity in THY culture supernatants (A600 = 1.1). Similar data were obtained at A600 = 0.6 
(results not shown). (C) Group A streptococcal cell-surface plasmin activity following 3h 
incubation in plasma (filled bars) or plasminogen-depleted plasma (hatched bars). Streptokinase 
alleles for each strain were as follows: NS53, subcluster 1; NS13, subcluster 2b; NS32, 
subcluster 2b; NS931, subcluster 1; NS730, subcluster 1; NS474, subcluster 1. All measurements 
represent mean (± SD) of triplicate determinations. 
 
Figure 2. Immuno-electron microscopy revealing the asymmetric distribution of SpeB [34], SEN 
[22,33] and GAPDH [33,35] on the GAS cell surface. Clusters of immuno-gold particles are boxed. 
 
Figure 3. Schematic diagram summarising the possible pathways of cell surface plasmin 
acquisition by various S. pyogenes strains. Plasminogen is a single chain 791 amino acid 
glycoprotein containing seven distinct structural domains, which are designated the amino-terminal 
peptide (NTP) followed by Kringles 1–5 (K1-5) and the carboxy terminal serine protease domain 
(PD). K1, K2, K4 and K5 contain lysine-binding motifs that are responsible for binding to 
fibrinogen and to plasminogen receptors. Lysine-dependent interaction/s between the NTP and K5 
are also responsible for maintaining the circulating zymogen in a mostly closed, activation-resistant 
form. As summarised here, the efficient conversion of plasminogen to its activated twin-chain form 
plasmin (depicted by loss of the NTP and by the green coloured PD linked to the kringle domains 
via a disulphide bond shown in red) by mammalian or microbial activators requires a binding-
induced conformational change in plasminogen to an open, activation-susceptible form [20,38,50]. 
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(A). Plasminogen bound directly to the cell surface via PAM, or other plasminogen receptors (PL-
R), or indirectly via fibrinogen receptors (F-R; not shown) may be activated to plasmin by host 
activators. (B) Streptokinase contains three structural domains designated the α, β  and γ domains, 
all of which can bind to the PD resulting in the streptokinase-plasminogen activator complex. 
Generally PAM negative strains secrete subcluster 1 or 2a allele forms of streptokinase [43] which 
can readily interact with solution phase (free), closed plasminogen (via K5; [50]). This results in a 
free activator complex that can convert other free plasminogen molecules to plasmin that can then 
readily bind to the cell surface directly via plasmin(ogen) receptors (e.g. SEN, GAPDH). 
Alternatively, the activator complex can bind to fibrinogen to form the fibrinogen-streptokinase-
plasminogen trimolecular complex. This can then bind to the cell surface via fibrinogen receptors 
and act on either directly or indirectly bound plasminogen leading to cell surface plasmin. (C) Most 
PAM-positive strains secrete subcluster 2b allele forms of streptokinase (hatched) which 
preferentially interact with an open conformation of plasminogen that is induced by binding to 
PAM via K2. The PAM-bound activator complex can then either activate free plasminogen to 
plasmin that can readily bind to the cell surface (via PAM and/or other receptors not shown here), 
or other PAM-bound plasminogen to plasmin. In both cases, this results in cell surface bound 
plasmin. Although not shown here, the PAM-bound activator complex could also act on indirectly 
bound plasminogen (via fibrinogen receptors). In all scenarios, bound plasmin is resistant to 
inhibition by α2-antiplasmin. In addition, free or PAM-bound streptokinase-plasminogen activator 





   19 
Text Box: 
Classification of group A streptococcal infection. 
I. Streptococcal toxic shock syndrome (STSS): Defined as a definite case by isolation of group 
A streptococci from a normally sterile site (eg. blood cerebrospinal, pleural or peritoneal fluid, 
tissue biopsy, surgical wound etc.) or a probable case if isolated from a non-sterile site (eg. 
Throat, sputum, vagina, superficial skin lesion etc.) in conjunction with combinations of the 
following signs of clinical severity; hypotension, renal impairment, coagulopathy, increased 
liver activity, adult respiratory distress syndrome, generalised erythematous rash or soft-tissue 
necrosis. 
II. Other invasive infections: Defined by isolation of group A streptococci from a normally 
sterile site in patients not meeting criteria for STSS 
a. Bacteremia with no identified focus 
b. Focal infections with or without bacteremia. Includes meningitis, pneumonia, 
peritonitis, puerperal sepsis, osteomyelitis, septic arthritis, necrotizing fasciitis, 
surgical wound infections, erysipeas and cellulitis. 
III. Scarlet Fever: Defined by a scarletina rash with evidence of group A streptococcal infection, 
most commonly pharyngotonsillitis. 
IV. Non-invasive infections: Defined by the isolation of group A streptococci from a non-sterile 
site. 
a. Mucous membrane: includes pharyngitis, tonsillitis, otitis media, sinusitis, vaginitis 
b. Cutaneous: includes impetigo. 
V. Non-suppurative sequelae: Defined by specific clinical findings with evidence of a recent 
group A streptococcal infection 
a. Acute rheumatic fever 
b. Acute glomerulonephritis
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